Transforming Innovation into Impact.
Strategic Capital for Healthcare and Life Sciences
Transforming Innovation into Impact.
Strategic Capital for Healthcare and Life Sciences
About BioMedex Capital
Our Team
Our Innovation
Our Innovation
At BioMedex Capital, we have assembled a team of talented and dedicated professionals who are passionate about improving healthcare through biotechnology. Our team includes scientists, researchers, engineers, and business professionals, all of whom bring unique skills and perspectives to our work.
Our Innovation
Our Innovation
Our Innovation
Innovation is at the heart of what we do at BioMedex Capital. We are constantly pushing the boundaries of biotechnology and developing new products and therapies that have the potential to transform healthcare. Our focus on innovation has earned us a reputation as a leader in the biotech industry.
Our Impact
Our Innovation
Our Impact
We are proud of the impact that our biotech products and therapies have had on patient care. Our products have been used to diagnose and treat a wide range of health conditions, from cancer to infectious diseases. We are committed to continuing to develop innovative solutions that improve patient outcomes.
Our Services
Private Equity Investment
We provide growth and buyout capital to companies across the healthcare value chain. Our investments typically range from $10M to $49M.
Strategic Advisory
We support portfolio companies with go-to-market strategy, clinical development guidance, regulatory planning, M&A support, and commercial scaling.
Operational Support
We embed our operating partners and advisors into each company we back, offering world-class capabilities in manufacturing, R&D, pricing/reimbursement, and global expansion.
We can help founders, licensees, and inventors buy out royalty rights from academic institutions, co-developers, or early investors—allowing them to consolidate ownership and unlock future upside.
Royalty Financing
We specialize in structured royalty transactions that provide non-dilutive capital to companies with commercial or near-commercial assets. Our royalty investments are designed to align with product cash flows and long-term business goals.
Key Offerings:
- Royalty Monetization (existing or future)
- Synthetic Royalty Structures
- Hybrid Equity + Royalty Deals
- Development-Stage Royalty Advances
- Milestone-Based Payouts
Revenue Interest Financing
A flexible alternative to traditional debt, revenue interest financing allows companies to access capital in exchange for a capped percentage of future revenue, often tied to one or more products or therapeutic franchises.
Why Choose It:
- No equity dilution
- Aligns repayment with product performance
- Retain operational control and IP
- Ideal for companies with predictable, growing revenue
Product Acquisition Financing
We partner with acquirers and licensees to provide structured capital for royalty-accretive M&A, asset purchases, or in-licensing transactions. Our team brings deep experience in product diligence and risk-sharing structures.
Solutions Include:
- Co-investment for commercial-stage assets
- Backing royalty buyouts or product carve-outs
- Shared-risk milestone-based acquisition support
IP-Backed Lending & Securitization
Our structured finance team offers innovative lending solutions secured against intellectual property portfolios, including royalties, patents, and market exclusivity rights.
We Offer:
- Term loans collateralized by royalty streams
- Asset-backed securitizations (ABS)
- Portfolio-based cash flow modeling
- IP valuation and monetization planning